Pangaea is currently laying the organizational groundwork for an ongoing program in Zimbabwe aimed at reducing HIV and maternal, child and infant morbidity and mortality by working with public and private partners to strengthen and integrate health systems at the district level.
Pangaea’s partners on the project will include Africa University, University of Zimbabwe, and the Chitungwiza Hospital Opportunistic Infection Clinic. The project leadership team will include Pangaea CMO Dr. Dennis Israelski, VP for Programs Dr. Megan Dunbar, Dr. Nancy Padian of Pangaea/UC Berkeley, Dr. Gerard Kadzirange of University of Zimbabwe, Dr. Abigail Kagwende and Dr. Jonathan Pfumojena of Africa University, Dr. David Katzenstein of Pangaea/Stanford, and Dr. Chris Seebregst, PhD of Pangaea/Jembi International.
Tanzania is poised to become the first country in sub-Saharan Africa to provide comprehensive treatment for both drug addiction and HIV to injection drug users (IDU’s), including a methadone treatment program. A joint announcement by the Tanzanian and U.S. governments was made about the program on May 18, 2010. Two pilot methadone clinics are scheduled to open in Dar es Salaam later this year as the first phase of this effort gets underway.
Pangaea has received a two-year $2.4 million grant from the Bill & Melinda Gates Foundation to support efforts by the Chinese Ministry of Health and China-based nongovernmental organizations (NGOs) to create a sustainable model of HIV prevention that demonstrates the feasibility of reducing new HIV infections throughout China.
Over the grant period, Pangaea will provide technical assistance to national partners within the Ministry of Health and selected NGOs to assist them in developing new models for successful HIV prevention.